Business Context and Reporting Period
This Form 8-K filing by Madrigal Pharmaceuticals, Inc. (MDGL) was submitted on July 11, 2019. The report discloses the appointment of a new officer and associated compensatory arrangements effective as of June 27, 2019, with public announcement on July 11, 2019.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes and compensation adjustments.
Material Changes
The primary material change is the appointment of Dr. Rebecca Taub as President of Research & Development. Dr. Taub previously served as Chief Medical Officer, Executive Vice President, Research and Development, and a Director since July 2016. She will continue to serve as a member of the Board of Directors.
Management Commentary and Compensation Details
In connection with the appointment, the Compensation Committee approved the following adjustments on July 10, 2019:
- Base Salary: Increased to $475,000 per annum (previously $454,000).
- Target Bonus: Increased to 50% of base salary under the Annual Cash Incentive Plan (previously 40%).
- Equity Award: Granted 8,000 stock options with an exercise price of $101.30 per share under the Amended 2015 Stock Plan.
The filing incorporates by reference Dr. Taub's business experience and relationship details from the Proxy Statement filed on May 15, 2019.
Investor Verification Checklist
- Verify the impact of the leadership change on the company's research and development pipeline.
- Review the May 15, 2019 Proxy Statement for Dr. Taub's full background and prior compensation history.
- Confirm the dilution impact of the 8,000 stock options granted.
- Monitor future filings for any additional executive appointments or compensation adjustments.